Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCall/ --

3Q09 Corporate Highlights:

  • Completed transfer of Qutenza(TM) E.U. Marketing Authorization to Astellas Pharma Europe Ltd.
  • Made significant progress in commercial readiness activities
  • Expanded management team to include VP Sales; Senior Director, Marketing; and Director, Commercial Operations
  • Appointed Bradford S. Goodwin to board as director and Audit Committee chairman

Upcoming 2009 Milestones:

  • FDA PDUFA date November 16, 2009 for Qutenza NDA to manage pain associated with PHN

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the third quarter ended September 30, 2009.

During the third quarter of 2009, NeurogesX prioritized three key initiatives: 1) supporting the ongoing U.S. Food and Drug Administration (FDA) review of the new drug application (NDA) for Qutenza for postherpetic neuralgia (PHN), 2) preparing for potential commercial launch of Qutenza in the United States pending FDA approval and 3) supporting Astellas Pharma Europe Ltd., the commercial partner for Qutenza in Europe, the Middle East and Africa, in their efforts to prepare for a Qutenza launch in the European Union in 2010.

In the U.S., NeurogesX is currently awaiting a decision from FDA regarding its NDA for Qutenza to manage pain associated with PHN. The agency has assigned an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009. In preparation for the possible approval and subsequent planned launch of Qutenza in the United States in the first half of 2010, the Company continued to make significant advances in a number of key product laun
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... ... office , ... Ill. (Vocus) December 9, 2009 -- As part of ongoing efforts to expand deployment ... in the contaminated soil , sediment and groundwater remediation industry, is ...
... , , WALTHAM, Mass., Dec. 8 ... Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will ... at 8:30 a.m. EST, to discuss results of its Phase 3 ... , This call is being webcast by Thomson/CCBN and can ...
... , CLEVELAND, ... high-performance products to the market with a Smart ... performance and recyclable packaging, Nutek,s products continue to ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091208/CL22934 ) ...
Cached Biology Technology:Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 2Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 3Nutek, LLC Introduces New Soy-Based, Biodegradable Lubricating and Cleaning Wipes 2
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
(Date:10/14/2014)... new kind of stem cell that can become either a ... according to a study published today in the journal ... type contradicts current theory on how organs arise from cell ... of, and future treatment for, liver cancer., Thanks to stem ... being made up of more than 200 cell types. The ...
(Date:10/14/2014)... MA – A team of scientists led by ... (UMMS) and the University of Miami Miller School ... a key genetic pathway underlying bipolar (manic depressive) ... drugs for treating bipolar affective disorder, as well ... The new findings, published online this week in ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... Now, a St. Louis-area teenage boy and a computer ... conducted by a team of neurosurgeons, neurologists, and engineers ... boy, a 14-year-old who suffers from epilepsy, is the ... Invaders, using only the signals from his brain to ...
... In a study appearing in the forthcoming issue of ... Tyre, and Svata M. Louda (all of the University ... aren't all eaten at the same rate. , ... the nutritional quality or defective chemistry of plant tissues. ...
... speed healing at sites of injury - such as heart ... stroke - doctors would like to be able to hasten ... to "mobilize" patients' blood vessel-forming cells, called angiogenic cells, so ... at Washington University School of Medicine in St. Louis demonstrated ...
Cached Biology News:Teenager moves video icons just by imagination 2Teenager moves video icons just by imagination 3Drug can quickly mobilize an army of cells to repair injury 2